Analysts Set GRAIL, Inc. (NASDAQ:GRAL) Target Price at $107.83

GRAIL, Inc. (NASDAQ:GRAL) has been given an average recommendation of “Hold” by the six brokerages that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $90.1667.

Several brokerages have recently weighed in on GRAL. Guggenheim upped their price target on shares of GRAIL from $100.00 to $130.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. TD Cowen assumed coverage on shares of GRAIL in a research note on Thursday, February 19th. They issued a “hold” rating and a $114.00 price objective for the company. Morgan Stanley lowered their target price on GRAIL from $110.00 to $60.00 and set an “equal weight” rating for the company in a report on Tuesday. Canaccord Genuity Group cut their price target on GRAIL from $105.00 to $80.00 and set a “buy” rating on the stock in a report on Friday, February 20th. Finally, Robert W. Baird set a $82.00 price target on GRAIL in a research report on Friday, February 20th.

GRAIL Trading Up 2.9%

Shares of GRAIL stock opened at $51.79 on Thursday. The stock’s fifty day moving average price is $94.24 and its 200-day moving average price is $76.55. The firm has a market cap of $2.02 billion, a P/E ratio of -4.63 and a beta of 4.52. GRAIL has a 12 month low of $20.44 and a 12 month high of $118.84.

GRAIL (NASDAQ:GRAL) last issued its earnings results on Thursday, February 19th. The company reported ($2.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.33) by $0.89. The company had revenue of $43.60 million for the quarter, compared to analysts’ expectations of $43.33 million. GRAIL had a negative net margin of 277.46% and a negative return on equity of 17.58%. Analysts forecast that GRAIL will post -15.15 earnings per share for the current year.

Hedge Funds Weigh In On GRAIL

A number of large investors have recently added to or reduced their stakes in GRAL. Caxton Associates LLP purchased a new position in shares of GRAIL during the 2nd quarter valued at about $3,320,000. NWF Advisory Services Inc. acquired a new stake in GRAIL during the second quarter worth about $1,062,000. Y Intercept Hong Kong Ltd purchased a new position in GRAIL during the third quarter valued at approximately $885,000. Legal Advantage Investments Inc. purchased a new position in GRAIL during the third quarter valued at approximately $1,242,000. Finally, Sheets Smith Investment Management acquired a new position in GRAIL in the third quarter valued at approximately $1,689,000.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.